Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting hypoxic response for cancer therapy.
Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. Paolicchi E, et al. Among authors: gemignani f. Oncotarget. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229. Oncotarget. 2016. PMID: 26859576 Free PMC article. Review.
Expression status of candidate genes in mesothelioma tissues and cell lines.
Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S. Melaiu O, et al. Among authors: gemignani f. Mutat Res. 2015 Jan;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13. Mutat Res. 2015. PMID: 25771974 Clinical Trial.
Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome.
Naccarati A, Rosa F, Vymetalkova V, Barone E, Jiraskova K, Di Gaetano C, Novotny J, Levy M, Vodickova L, Gemignani F, Buchler T, Landi S, Vodicka P, Pardini B. Naccarati A, et al. Among authors: gemignani f. Oncotarget. 2016 Apr 26;7(17):23156-69. doi: 10.18632/oncotarget.6804. Oncotarget. 2016. PMID: 26735576 Free PMC article.
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddis R, Cristaudo A, Gemignani F, Landi S. De Santi C, et al. Among authors: gemignani f. Occup Environ Med. 2017 Jun;74(6):456-463. doi: 10.1136/oemed-2016-104024. Epub 2017 Mar 25. Occup Environ Med. 2017. PMID: 28343162 Free article.
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, Melaiu O, Giordano A, Luzzi L, Gemignani F, Landi S. Dell'Anno I, et al. Among authors: gemignani f. Invest New Drugs. 2021 Jun;39(3):644-657. doi: 10.1007/s10637-020-01040-y. Epub 2020 Dec 9. Invest New Drugs. 2021. PMID: 33300108 Free PMC article.
Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding.
Pardini B, Rosa F, Barone E, Di Gaetano C, Slyskova J, Novotny J, Levy M, Garritano S, Vodickova L, Buchler T, Gemignani F, Landi S, Vodicka P, Naccarati A. Pardini B, et al. Among authors: gemignani f. Clin Cancer Res. 2013 Nov 1;19(21):6044-56. doi: 10.1158/1078-0432.CCR-13-0314. Epub 2013 Sep 13. Clin Cancer Res. 2013. PMID: 24036853
267 results